4.6 Article

Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma

Journal

Publisher

ELSEVIER
DOI: 10.1016/j.jpba.2022.114980

Keywords

Psychedelics; Drug metabolism; Pharmacokinetics; Liquid chromatography; Tandem Mass spectrometry; Forensics

Funding

  1. Swiss National Science Foundation (SNF) [32003B_185111/1]
  2. Mind Medicine Inc.

Ask authors/readers for more resources

In this study, a bioanalytical method was developed for the rapid quantification of mescaline and its metabolites in human plasma. The method showed reliability and ease of use, making it suitable for forensic applications as well as investigating the clinical pharmacokinetics of mescaline.
Mescaline is a psychedelic phenethylamine found in different species of cacti. Currently, mescaline's acute subjective effects and pharmacokinetics are investigated in several modern clinical studies. Therefore, we developed a bioanalytical method for the rapid quantification of mescaline and its metabolites in human plasma. Mescaline and its metabolites 3,4,5-trimethoxyphenylacetic acid (TMPAA), N-acetyl mescaline (NAM), and 3,5-dimethoxy-4-hydroxyphenethylamine (4-desmethyl mescaline) were simultaneously analyzed by ultra-high performance liquid chromatography tandem mass spectrometry (LC-MS/MS). Optimal chromatographic separation was achieved with an Acquity Premier HSS T3 C-18 column. The analytes were detected in positive ionization mode using scheduled multiple reaction monitoring. A single step extraction method was implemented to enable fast and automatable plasma sample preparation. An intra-assay accuracy between 84.9% and 106% and a precision of <= 7.33% was observed in three validation runs. Plasma was extracted by simple protein precipitation, resulting in a complete recovery (>= 98.3%) and minor matrix effects (<= 7.58%). No interference with endogenous matrix components could be detected in human plasma samples (n = 7). Importantly, method sensitivity sufficed for assessing pharmacokinetic parameters of mescaline in clinical study samples with lower limits of quantification of 12.5, 12.5, and 1.25 ng/mL for mescaline, TMPAA, and NAM, respectively. Nonetheless, 4-desmethyl mescaline could not be selectively quantified in pharmacokinetic samples due to interference with another mescaline metabolite. Overall, we developed and validated a reliable and very easy-to-use method for forensic applications as well as investigating the clinical pharmacokinetics of mescaline.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available